Bilgiç Özlem
a Department of Dermatology , Faculty of Medicine, Selcuk University , Konya , Turkey.
Cutan Ocul Toxicol. 2016 Dec;35(4):329-31. doi: 10.3109/15569527.2015.1100635. Epub 2015 Oct 29.
Vemurafenib, a novel treatment for patients with BRAF-positive metastatic melanoma, is associated with a wide spectrum of cutaneous adverse events both benign and malignant. Vemurafenib-induced pityriasis amiantacea (PA), a scaling reaction of the scalp that may cause temporary or cicatricial alopecia, has not yet been reported in the literature. In the present case, PA was observed two months after the initiation of vemurafenib therapy for metastatic melanoma and managed with symptomatic treatment without the need to cease or modify the vemurafenib dosage.
维莫非尼是一种用于治疗BRAF阳性转移性黑色素瘤患者的新型药物，它会引发一系列广泛的皮肤不良事件，包括良性和恶性的。维莫非尼诱发的石棉状糠疹（PA），即头皮的一种脱屑反应，可能导致暂时性或瘢痕性脱发，目前文献中尚未有相关报道。在本病例中，转移性黑色素瘤患者在开始使用维莫非尼治疗两个月后出现了PA，通过对症治疗进行处理，无需停用或调整维莫非尼剂量。
